Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
HCV: The Journey from Discovery to a Cure : Volume II / / edited by Michael J. Sofia
| HCV: The Journey from Discovery to a Cure : Volume II / / edited by Michael J. Sofia |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (VIII, 500 p. 50 illus., 20 illus. in color.) |
| Disciplina |
616.362306
616.3623 |
| Collana | Topics in Medicinal Chemistry |
| Soggetto topico |
Medicinal chemistry
Virology Medical biochemistry Bioorganic chemistry Pharmaceutical technology Medicinal Chemistry Medical Biochemistry Bioorganic Chemistry Pharmaceutical Sciences/Technology |
| ISBN | 3-030-28400-X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | NS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi® -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIER® -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure. |
| Record Nr. | UNINA-9910377840203321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
HCV: The Journey from Discovery to a Cure : Volume I / / edited by Michael J. Sofia
| HCV: The Journey from Discovery to a Cure : Volume I / / edited by Michael J. Sofia |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (viii, 463 pages) |
| Disciplina | 616.362306 |
| Collana | Topics in Medicinal Chemistry |
| Soggetto topico |
Medicinal chemistry
Virology Medical biochemistry Bioorganic chemistry Pharmaceutical technology Medicinal Chemistry Medical Biochemistry Bioorganic Chemistry Pharmaceutical Sciences/Technology |
| ISBN | 3-030-28207-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Identification of the virus, the medical need and clearing the blood supply -- Mapping the HCV genome -- The molecular virology of HCV -- The development of the HCV replicon system -- The Evolution of IFN therapy for HCV -- Evolution of HCV NS5B Non-Nucleoside Inhibitors -- Evolution of HCV NS5B Nucleoside & Nucleotide Inhibitors -- Discovery and Development of Sofosbuvir -- Discovery of Beclabuvir -- Discovery of Dasabuvir -- Evolution of HCV NS3/4 protease inhibitors -- Discovery and Development of Telaprevir -- Discovery and Development of Boceprevir -- Discovery and Development of Asunaprevir.-Discovery and Development of Grazoprevir -- Discovery and Development of Simeprevir -- Discovery and Development of Paritaprevir & Glecaprevir. |
| Record Nr. | UNINA-9910357822903321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||